H.C. Wainwright analyst Vernon Bernardino downgraded Acer Therapeutics (ACER) to Neutral from Buy without a price target after Zevra Therapeutics (ZVRA) announced it would acquire Acer in a merger transaction having a total potential value for Acer stockholders of up to $91M. The firm is positive on the deal as it believes the addition of Olpruva and Edsivo is synergistic with Zevra’s rare disease portfolio, which increases Olpruva’s chances for a successful U.S. launch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACER:
- Acer Therapeutics downgraded to Neutral from Buy at Roth MKM
- Acer Therapeutics (NASDAQ:ACER) Skyrockets 136% on Acquisition News
- Zevra Therapeutics to acquire Acer Therapeutics in potential $91M transaction
- Acer Therapeutics regains exclusive worldwide rights to OLPRUVA
- Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe